CD47 and brain neoplasm: Mice that had been orthotopically xenografted with primary brain tumor cells from a low-passage primary glioma line (GBM5) or a different, highly aggressive glioma cell line (GBM4), and confirmed by bioluminescence imaging, were subsequently treated with either anti-CD47 antibody or control for 4 weeks (1 week in case of engrafted GBM4) after tumor induction.